What is the ticker symbol for TCR2 Therapeutics?

TCR2 Therapeutics trades under the ticker TCRR on NASDAQ.

What sector does TCR2 Therapeutics operate in?

TCR2 Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TCRR in a portfolio?

PortView shows TCRR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

TCR2 Therapeutics (TCRR) Stock Analysis

NASDAQHealthcareBiotechnology

$1.48+0.00%

1-year price historyRange $0.83 – $3.75

52-week range$1.48

$0.82$3.88

What TCR2 Therapeutics does

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.

Key metrics

Market cap

$58.11M

P/E (TTM)

-0.35

EPS (TTM)

$-4.20

Beta

1.93

Dividend yield

0.00%

Revenue / share

$0.00

50-day avg

$1.69

200-day avg

$1.56

52-week high

$3.88

52-week low

$0.82

CEO

Garry E. Menzel

ETFs linked to TCRR

Broad-market and Healthcare sector ETFs an investor holding TCR2 Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how TCRR fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze TCRR in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for TCR2 Therapeutics?: TCR2 Therapeutics trades under the ticker TCRR on NASDAQ.
Which exchange is TCRR listed on?: TCRR is listed on NASDAQ.
What sector does TCR2 Therapeutics operate in?: TCR2 Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze TCRR in a portfolio?: PortView shows TCRR's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.